Amylyx Pharmaceuticals (AMLX)
(Delayed Data from NSDQ)
$1.82 USD
-0.05 (-2.67%)
Updated May 15, 2024 04:00 PM ET
After-Market: $1.82 0.00 (0.00%) 7:00 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AMLX 1.82 -0.05(-2.67%)
Will AMLX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AMLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMLX
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
AMLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70%
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
Other News for AMLX
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Wave Life Sciences (WVE) and GoodRx Holdings (GDRX)
Amylyx price target lowered by $1 at Mizuho, here's why
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), IN8bio (INAB) and Privia Health Group (PRVA)
Bank of America Securities Keeps Their Hold Rating on Amylyx Pharmaceuticals Inc (AMLX)
Buy Rating Affirmed for Amylyx Pharmaceuticals on Positive ALS and Wolfram Syndrome Trials